Lifeway Foods, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparative period is Q1 2023. Financial statement amounts below are in millions of dollars unless stated otherwise.
Business context
Lifeway makes and markets cultured dairy products, primarily drinkable kefir, under Lifeway and other brands, as well as private labels. It reports as one operating segment; substantially all sales are cultured dairy products sold in the United States. Drinkable kefir other than ProBugs represented 82% of Q1 sales. Two major customers accounted for approximately 25% of sales in Q1 2024, compared with approximately 24% in Q1 2023.
Financial performance
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net sales | $44.634 | $37.904 |
| Gross profit / margin | $11.535 / 25.8% | $8.226 / 21.7% |
| Operating income / margin | $3.564 / 8.0% | $1.437 / 3.8% |
| Net income / margin | $2.426 / 5.4% | $0.830 / 2.2% |
| Diluted earnings per share | $0.16 | $0.06 |
| Operating cash flow | $1.546 | $3.027 |
| Capital expenditures | $2.469 | $1.762 |
Sales rose 17.8%, primarily on higher volumes of branded drinkable kefir. Gross margin improved, which management attributed mainly to higher branded-product volumes and, to a lesser extent, lower transportation costs. Selling expense rose to $3.700 million, but declined as a share of sales to 8.3% from 9.3%. General and administrative expense increased $1.001 million to $4.136 million, primarily due to incentive compensation and non-routine stockholder-action expense.
Operating cash flow declined year over year, reflecting working-capital changes, partly offset by higher cash earnings and lower costs for certain inputs. Cash flow less capital expenditures was negative $0.923 million, compared with positive $1.265 million in Q1 2023. Capital spending increased as planned and focused on growth, cost reduction, and facility improvements.
Balance sheet, debt and liquidity
At March 31, 2024, cash was $12.025 million, current assets $37.585 million, and current liabilities $14.878 million; working capital was $22.707 million. The current ratio was approximately 2.5. Total assets were $82.751 million and stockholders’ equity was $63.535 million. Cash declined $1.173 million during the quarter.
Term-loan principal was $2.500 million (reported note payable, net of financing costs, was $2.485 million); the loan bears interest at 7.39% and matures in August 2026. There were no revolver borrowings, and $5.000 million remained available under the revolving facility. The company reported compliance with its financial covenants, including a minimum working-capital covenant of $11.25 million. Management said cash, operating cash flow, and available credit should provide sufficient liquidity for operations, capital needs, and growth initiatives.
Outlook, risks and unusual items
- Management expects inflationary pressures to be moderate in 2024. It reported no significant supply-chain disruptions or labor shortages and said it continued to meet customer demand. The filing provides no quantified sales or earnings guidance.
- Risks identified include commodity-price changes, competitive pricing and customer decisions, execution of business strategy, regulation, and supply-chain or manufacturing and distribution disruptions, including cybersecurity threats. Management cautioned that a serious economic or credit-market crisis could adversely affect liquidity and results.
- The company is involved in ordinary-course legal matters. No individual or aggregate accrual was considered material, and management did not expect the matters’ resolution to have a material adverse effect; an adverse outcome could nevertheless have a material effect.
- The effective tax rate was 30.8%, versus 37.9% in Q1 2023; management attributed the difference in part to the varying percentage effect of nondeductible and other tax items against different pretax income levels.
- Disclosure controls were assessed as effective at quarter-end. The filing reported no material change in internal control over financial reporting and no material change to the risk factors in the 2023 Form 10-K.
Key investor verification points
- Confirm whether sales growth and margin gains continue, and how much they depend on branded kefir volumes, input costs, and transportation costs.
- Track working-capital movements and operating cash generation against the increased capital-spending program.
- Assess the scale and recurrence of incentive compensation and non-routine stockholder-action costs within G&A.
- Monitor customer concentration, debt repayment, revolver availability, and ongoing compliance with loan covenants.
- Review subsequent disclosures for developments in litigation, commodity inflation, supply-chain risks, and any formalized outlook.